Suggestions
Jonas Jendi
Chief Investment Officer & Head of Analysis at Industrifonden
Jonas Jendi is a senior executive at Industrifonden, a Swedish venture capital firm. His current roles include Chief Operating Officer (COO), Practice Lead for Life Science, and Senior Investment Director.1 He joined Industrifonden in 2017 and has since been focused on investments in the life sciences sector, while also supporting the investment process across all areas of the fund.1
Professional Background
Jonas has over 20 years of experience in early-stage startups and venture capital. His career journey includes:
- CEO of Cogmed Systems AB from 2002 to 2007, where he led the company from a research-based startup to a globally implemented intervention.2
- Various board and advisory roles in biotech, healthtech, and edtech companies between 2012 and 2017.2
- Independent consultant and board member for several companies, including BioInvent and Diamyd Medical.2
- Earlier in his career, he worked as a consultant at The Boston Consulting Group in Stockholm and Paris.2
Education and Interests
Jonas holds a Master of Science degree from the Stockholm School of Economics.1 He has a keen interest in novel innovations and the complex process of turning radical ideas into successful businesses.1 His areas of expertise include diagnostics, healthtech, medtech, therapeutics, biotech, and digital health.1
Recent Activities
At Industrifonden, Jonas has been involved in various investments and portfolio companies:
- In October 2021, he led a €5 million growth investment in TrusTrace.3
- He has been active in promoting and supporting portfolio companies like Asgard Therapeutics, which recently published research in Science Immunology.5
- Jonas regularly participates in industry events such as the NLS Days (Nordic Life Science Days).4
Jonas Jendi's role at Industrifonden involves not only making investment decisions but also building the analyst team and supporting the overall investment process across the fund.1 His experience and expertise make him a key figure in Sweden's venture capital and life sciences ecosystem.